Clinical trials: SGLT2-Inhibitors
Prediabetes
Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes
Prediabetes effects 96 million people 18 years of age or older. It is important to identify treatment options to slow or prevent progression to diabetes.
- Trial name
- PREVNT (NCT06828731)
- Testing
- Empagliflozin 10mg daily, Lifestyle education
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Charles George VA Medical Center
Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications
Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors
Inhibition of dipeptidyl peptidase-4 (DPP-4) or sodium-glucose co-transporter type 2 (SGLT2) has been proposed as a therapeutic target for type 2 diabetes.
- Trial name
- NCT02528019
- Testing
- DPP-4 inhibiotors, SGLT2 inhibitors, Glimepiride
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Kurume University
Acute Myocardial Infarction (AMI), Type 2 Diabetes Mellitus (T2DM)
SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study
This observational, retrospective cohort study aims to evaluate the impact of sodium-glucose cotransporter 2 (SGLT2) inhibitor use after acute myocardial infarction (AMI) in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- SGLT2i-AMI (NCT07198191)
- Testing
- SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin), DPP4 inhibitors
- Where
- South Korea
- Volunteers
- 200,000 people
- Sponsor
- Yonsei University
Heart Failure Acute, Ventilator Lung
SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning
This study will explore the potential benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors in preventing cardiac ischemia and cardiopulmonary edema in patients with acute decompensated heart failure during weaning from…
- Trial name
- NCT06142474
- Testing
- SGLT2 inhibitor
- Where
- Taiwan
- Volunteers
- 450 people
- Sponsor
- National Taiwan University Hospital
Type 2 Diabetes
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a…
- Trial name
- NCT06297603
- Testing
- Retatrutide
- Where
- 76 sites in United States, Argentina and 5 more
- Volunteers
- 320 people
- Sponsor
- Eli Lilly and Company
SLE, Lupus Nephritis
Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
This study aims to assess sodium glucose linked transoprter inhibitors(SGT2i) role in regression of ongoing kidney and cardiac diseases among lupus nephritis patient either diabetic or non-diabetic under different…
- Conditions
- SLE, Lupus Nephritis, SGLT2 Inhibitors
- Trial name
- NCT05748925
- Testing
- dapagliflozin
- Where
- Egypt
- Volunteers
- 84 people
- Sponsor
- Mansoura University
Retinal Degeneration, Retinal Diseases
SGLT2 Inhibitors in Geographic Atrophy
AMD is a leading cause of blindness in individuals over 50 years old, with dry AMD being the most common form. Geographic atrophy (GA) is an advanced stage of dry AMD characterized by progressive retinal cell degeneration.
- Conditions
- Retinal Degeneration, Retinal Diseases, Eye Diseases, Geographic Atrophy
- Trial name
- NCT07174687
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Washington University School of Medicine
Acute Myocardial Infarction, Heart Failure
Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention
We aimed to identify whether SGLT-2 inhibitor administration before and after coronary intervention is effective in reducing the size of infarction and myocardial remodeling in patients with acute myocardial infarction (AMI) and…
- Trial name
- PRESTIGE-AMI (NCT04899479)
- Testing
- SGLT2 inhibitor, Control
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Type 2 Diabetes Mellitus, Mild Cognitive Impairment
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
This is an investigator-led prospective, randomized, open label, parallel study to explore and evaluate the therapeutic effects of Liraglutide, Empagliflozin and Linagliptin on the cognitive function in T2DM patients with mild…
- Trial name
- LIGHT-MCI (NCT05313529)
- Testing
- Liraglutide, Empagliflozin, Linagliptin
- Where
- 5 sites in China
- Volunteers
- 396 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Hypertrophic Cardiomyopathy, Heart Failure
Empagliflozin in Hypertrophic Cardiomyopathy
The proposed intervention will be administration of empagliflozin at a standard dose of 10 mg daily for a period of 12 months. Patients with diagnosed diabetes will be excluded from the study.
- Trial name
- EMPA-REPAIR (NCT05182658)
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in Poland
- Volunteers
- 250 people
- Sponsor
- National Institute of Cardiology, Warsaw, Poland
Type 2 Diabetes (T2DM)
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
Minorities have higher rates of diabetes, poorer glucose control, and higher complications and mortality rates than white people.
- Trial name
- Beta (NCT07325435)
- Testing
- SGLT-2 inhibitor, GLP1-RA
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- MaryAnn Banerji
Heart Failure
Informational Nudge to Improve Heart Failure Prescribing
This study addresses a critical gap of care for Veterans with heart failure (HF). Only 1/3 or fewer eligible Veterans are receiving recommended SGLT2 and MRA therapies that save lives and prevents HF hospitalizations.
- Trial name
- Nudge (NCT05986695)
- Testing
- Alert, Peer comparison report
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Chronic Kidney Disease Stage 5, CKD Stage 4
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease
The goal of this clinical trial is to evaluate whether dapagliflozin can reduce the risk of worsening kidney function or death from cardiovascular or renal causes in adults with advanced chronic kidney disease (CKD), with or…
- Trial name
- NCT06982079
- Testing
- Dapagliflozin 10 mg
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Type 2 Diabetes
TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.
The aim of this project is to identify subgroups of patients with type 2 diabetes that respond well or poorly to particular drugs based on particular clinical characteristics such as their weight or kidney function, to enable…
- Trial name
- TriMaster (NCT02653209)
- Testing
- Sitagliptin - DPP4i, Canagliflozin - SGLT2i, Pioglitazone - TZD
- Where
- United Kingdom
- Volunteers
- 525 people
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy
Efficacy and safety of early administration of the SGLT-2 inhibitor dapagliflozin will be evaluated in patients with HF, regardless of LVEF, due to amyloid cardiomyopathy.
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Amyloid Cardiomyopathy
- Trial name
- NCT05795400
- Testing
- Dapagliflozin 10mg Tab
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Diabetes, Diabetes Mellitus, Type 2
LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.
The trial is conducted in Asia, Europe, North America and South America. The aim of the study is to compare the effect of liraglutide 1.8 mg/day versus placebo as add-on to an SGLT2 inhibitor with or without metformin on…
- Trial name
- NCT02964247
- Testing
- liraglutide
- Where
- 82 sites in United States, Brazil and 5 more
- Volunteers
- 303 people
- Sponsor
- Novo Nordisk A/S
Metabolic Syndrome
Strategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET)
This study is a randomized, parallel-group, observer-masked clinical trial. A total of 200 obese participants with MetS will be enrolled.
- Trial name
- NCT06271200
- Testing
- Strategic lifestyle and drug interventions, Control
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Health Research Institutes, Taiwan
Septic Shock
Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction
Microcirculatory dysfunction is a key driver of organ failure and mortality in septic shock, characterized by endothelial injury and impaired vasoregulation.
- Trial name
- GLIFLOSHOCK (NCT07488689)
- Testing
- Dapaglifozin
- Where
- France
- Volunteers
- 568 people
- Sponsor
- University Hospital, Strasbourg, France
Postoperative Hyperglycemia, Stress Hyperglycemia
Treatment With SGLT-2 Inhibitor for Postoperative Hyperglycemia in Acute Abdominal Surgery - a Randomized Trial
The aim of the study is to investigate the effect of an SGLT-2 inhibitor on postoperative hyperglycemia after acute abdominal surgery in patients without diabetes
- Trial name
- NCT05314725
- Testing
- SGLT2 inhibitor
- Volunteers
- 24 people
- Sponsor
- Zealand University Hospital
SGLT 2 Inhibitors, Pediatric Kidney Disease
Efficacy and Safety of Dapagliflozin in Children With Proteinuria
This interventional study investigates the efficacy of dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, in pediatric patients with renal disease.
- Conditions
- SGLT 2 Inhibitors, Pediatric Kidney Disease, Proteinuric Diseases, Dapagliflozin (Forxiga)
- Trial name
- NCT07204743
- Testing
- Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy
- Where
- Palestinian Territories
- Volunteers
- 10 people
- Sponsor
- Al-Quds University